Positive Predictive Value and Biopsy Rate of Breast Cancer in BI-RADS Category 4 and 5 Breast Lesions
Keywords:
Breast Imaging Reporting and Data System (BI-RADS), mammography, breast cancer, positive predictive value (PPV), biopsy rate, BI-RADSAbstract
Objective: To determine positive predictive values (PPV) and biopsy rates of breast cancer in lesions categorized as BI-RADS (Breast Imaging Reporting and Data System) category 4 and 5.
Materials and methods: The medical and radiological records of women which diagnosed as BI-RADS 4 and 5 breast lesions at Prachuapkhirikhan Hospital from October 1, 2013 to October 31, 2017 were retrospectively studied. PPV was calculated for women who had biopsies with subsequent pathologic results. The radiographic and pathological reports were compared. Biopsy rates of the patients diagnosed as BI-RADS category 4 and 5 were analyzed.
Result: Total of 1,596 patients who underwent mammography at Prachuapkhirikhan Hospital, 312 of women who diagnosed for BI-RADS 4 and 5 were included. One hundred ninety five of women had tissue diagnoses which biopsy rate was about 62.5%. The biopsy rates categorized as BI-RADS 4 and 5 were 58.9% and 75.8%, respectively. The mean age was 50.1 years (range, 26-85). Mass without microcalcification was the most common mammographic imaging in this study. Eighty eight women had breast cancer. The most common malignancy was invasive ductal carcinoma. One hundred and seven women had benign features. The most common benign type was fibrocystic change. PPVs for subcategories 4 and 5 were about 27.6% and 96.0% respectively.
Conclusion: BI-RADS category is useful in predicting the chance of breast cancer. Biopsy should be performed in all suspect mammographic findings because overlapping malignant and benign lesions in some radiological appearances. PPVs of malignancy in BI-RADS category 4 and 5 were 27.6% and 96.0%, respectively. The biopsy rate was 62.5%
References
2. Hospital-based cancer registry. Bangkok: National Cancer Institute; 2015.
3. Kopans DB. Screening for breast cancer and mortality reduction among women 40-49 years of age. Cancer 1994;74:311-22.
4. Tabár L, Vitak B, Chen HH, et al. The Swedish two-county trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000;38:625-51.
5. American College of Radiology. Breast imaging reporting and data system, breast imaging atlas. 5th ed. Reston, VA: American College of Radiology; 2013.
6. Wiratkapun C, Bunyapaiboonsri W, Wibulpholprasert B, et al. Biopsy rate and positive predictive value for breast cancer in BI-RADS category 4 breast lesions. J Med Assoc Thai 2010;93:830-7.
7. Muttarak M, Srivichai K, Chaiwan B, et al. The breast imaging and data system-BIRADS: Positive predictive value of category 4 and 5 lesions. Chiangmai Med J 2010;49(3):111-6.
8. Sirikunakorn P, Marukatat M, Tangjitkamol S, et al. Positive predictive value of malignancy in BI-RADS 4 and 5 breast lesions. Vajira Med J 2014;58:1-11.
9. Yah-Yuan T, Siew-Bock W, Mona PC, et al. Positive predictive value of BI-RADS categorization in an Asian population. Asian J Surg 2004;27:186-91.
10. Zonderland HM, Pope TL Jr, Nieborg AJ. The positive predictive value of the breast imaging reporting and data system (BIRADS) as a method of quality assessment in breast imaging in a hospital population. Eur Radiol 2004;14:1743-50.
11. Lacquement MA, Mitchell D, Hollingsworth AB. Positive predictive value of the Breast Imaging Reporting and Data System. J Am Coll Surg 1999;189:34-40.
12. Wiratkapun C, Lertsithichai P, Wibulpholprasert B. Positive predictive value of breast cancer in the lesions categorized as BI-RADS category 5. J Med Assoc Thai 2006;89:1253-9.
Downloads
Published
How to Cite
Issue
Section
License
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
